Solo para uso en investigación de laboratorio. No es para consumo humano. No es para uso clínico ni terapéutico. No evaluado por la FDA.
Comparación de investigación
CJC-1295 vs. Tesamorelin
CJC-1295 and Tesamorelin are both GHRH analogs characterized at the GHRH receptor, but they are built differently. CJC-1295 (with DAC) is a 30-residue modified GRF(1-29) carrying an albumin-binding DAC group (3647.2 g/mol). Tesamorelin is a 44-residue GHRH(1-44) analog with an N-terminal trans-3-hexenoyl cap (5135.9 g/mol).
Tesamorelin
GHRH(1-44) analog with an N-terminal trans-3-hexenoyl cap; 44 residues.
| Atributo | CJC-1295 | Tesamorelin |
|---|---|---|
| Peptide class / structure | GHRH analog | GHRH analog |
| Parent sequence | GRF(1-29) | GHRH(1-44) |
| Key modification | Albumin-binding DAC group | N-terminal trans-3-hexenoyl cap; C-terminal amide |
| Length (residues) | 30 aa | 44 aa |
| Molecular formula | C165H269N47O46 | C221H366N72O67S |
| Molecular weight | 3647.2 g/mol | 5135.9 g/mol |
| CAS number | 446262-90-4 | 218949-48-5 |
| Supplied as | Lyophilized powder, 5 mg vial | Lyophilized powder, 5 mg vial |
| COA on file | Not yet | Yes (Kovera Labs) |
Preguntas frecuentes
Are CJC-1295 and Tesamorelin the same class of peptide?+
Both are GHRH analogs characterized at the GHRH receptor, but they differ in parent sequence and modification: CJC-1295 is a modified GRF(1-29) carrying an albumin-binding DAC group (30 residues), while Tesamorelin is a GHRH(1-44) analog with an N-terminal trans-3-hexenoyl cap (44 residues).
How do their molecular weights compare?+
CJC-1295 (with DAC) is C165H269N47O46 at 3647.2 g/mol; Tesamorelin is C221H366N72O67S at 5135.9 g/mol. Tesamorelin is the longer chain and the heavier molecule, and its formula includes a sulfur atom.
Is the CJC-1295 report on the COA page for this compound?+
No. That report tests CJC-1295 without DAC (5 mg), CAS 863288-34-0 — a different compound from the with-DAC CJC-1295 compared here (CAS 446262-90-4) — so it is not linked to this listing.